{"disease":{"id":"chronic-hepatitis-c-virus","name":"chronic hepatitis c virus"},"drugs":{"marketed":[],"pipeline":[{"drug_id":"odalasvir-25-mg","indication_name":"Chronic hepatitis C virus infection (genotypes 1–6)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 25 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT06596213","title":"Hepatitis Inequalities Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT02629172","title":"Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1","phase":"","overall_status":"COMPLETED","enrollment_count":3043,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT07274345","title":"Prevalence and Risk Factors of Antiviral Resistance in Egyptian HBV Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Amira Mohamed Zidan","has_results":false},{"nct_id":"NCT02219490","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1596,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04387526","title":"Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":946,"lead_sponsor_name":"Beni-Suef University","has_results":false},{"nct_id":"NCT02243293","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":694,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02167945","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":615,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02945228","title":"Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2","phase":"","overall_status":"COMPLETED","enrollment_count":449,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT02105467","title":"Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":421,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02707952","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":295,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT05904470","title":"A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":275,"lead_sponsor_name":"Atea Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04850950","title":"Tenofovir Alafenamide to Prevent Perinatal Transmission of Hepatitis B","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":240,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false},{"nct_id":"NCT04382937","title":"Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":222,"lead_sponsor_name":"PharmaEssentia","has_results":false},{"nct_id":"NCT02723084","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT03453346","title":"Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis C","phase":"NA","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Kawin Technology Share-holding Co., Ltd.","has_results":false},{"nct_id":"NCT04391985","title":"Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Beni-Suef University","has_results":false},{"nct_id":"NCT02517528","title":"ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT01740791","title":"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT02692703","title":"A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02442284","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":99,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04387539","title":"ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Beni-Suef University","has_results":false},{"nct_id":"NCT02292719","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02207088","title":"Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT03002818","title":"Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)","phase":"","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02219477","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT07487623","title":"Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study).","phase":"NA","overall_status":"RECRUITING","enrollment_count":26,"lead_sponsor_name":"University of Guadalajara","has_results":false},{"nct_id":"NCT04019717","title":"Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Atea Pharmaceuticals, Inc.","has_results":false}],"total":28},"guidelines":[],"source":"Drug Landscape verified database"}